Coronary Artery Disease
Medical Management of Coronary Artery Disease
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers before starting new treatments and for all medical decisions. Never delay seeking medical care based on content you have read.
These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.
In Brief
Understanding the clinical medical management of coronary artery disease requires recognizing that patients with established coronary artery disease typically take several medications — often a combination targeting different aspects of the disease. This can feel complex, and the rationale for each agent is not always explained clearly. Modern cardiovascular medicine works differently from how many people expect. CAD is systemic biology: plaque accumulation, inflammation, thrombosis risk, and metabolic dysfunction distributed throughout the coronary tree and beyond. Medications address this biology at the level of individual mechanisms. Procedures address focal anatomy. Both have roles, but they are not interchangeable. This article explains how medications work biologically, which ones prevent cardiovascular events versus control symptoms, how to think about combinations, and why the biology benefits from long-term consistency.
CAD Is Systemic Biology, Not a Plumbing Problem
The most important conceptual shift in understanding coronary artery disease treatment is this: CAD is not a focal obstruction problem that gets fixed when the obstruction is removed. It is a systemic biological disease affecting the entire coronary tree and beyond — driven by four interacting forces:
Haemodynamic forces — blood pressure, arterial stiffness, and the mechanical stress on vessel walls that determines how quickly endothelial injury accumulates.
Lipoprotein burden — the number of atherogenic particles (LDL, ApoB, Lp(a)) available to enter and accumulate within arterial walls over time. This is cumulative exposure biology — what matters is not today’s LDL number but the total particle exposure across decades.
Metabolic environment — insulin resistance, visceral adiposity, and glycation, which accelerate plaque formation and impair the biological processes that would otherwise stabilise it.
Trigger biology — inflammation, clotting tendency, and autonomic tone, which determine whether existing plaques remain biologically quiet or become vulnerable to rupture.
While mechanical interventions offer localized anatomical solutions, they possess distinct biological boundaries that mandate systemic pharmacotherapy:
- Focal limitation: A stent restores blood flow strictly within a single narrowed arterial segment but leaves the remaining coronary tree unaddressed.
- Inflammatory environment: Localized procedures cannot modify the systemic inflammatory state driving plaque instability in distant vascular zones.
- Lipoprotein accumulation: Mechanical revascularization does not reduce the circulating ApoB or LDL particle burden accumulating throughout the wider vascular system.
- Thrombosis risk management: Stenting cannot mitigate the systemic clotting tendencies that threaten healing arterial segments elsewhere.
- Foundational rationale: Medications function as primary therapy because they address the comprehensive, multi-vessel biology that focal procedures cannot reach.
Not all plaques are equally dangerous. This is one of the most important and least understood concepts in coronary disease. Patients naturally assume that the largest obstruction is the greatest threat. In reality, many heart attacks arise from plaques that were not severely obstructing blood flow — plaques that were biologically unstable, with thin fibrous caps and large inflammatory lipid cores, that ruptured without warning and triggered sudden clot formation.[24] A 40% narrowing that is lipid-rich, inflamed, and structurally fragile can be more dangerous than a heavily calcified 80% narrowing that has been stable for years. This explains why procedures that eliminate one visible blockage do not eliminate future event risk: the biology that created that plaque is still present throughout the vascular tree.
Symptoms and risk are not the same thing. A patient can have severe angina from a flow-limiting obstruction without being at high short-term risk of infarction. The same patient may have less symptomatic disease elsewhere that carries higher rupture risk. Symptom relief and event prevention are genuinely different goals that sometimes require different approaches.[3,8] Medications that prevent heart attacks often produce no noticeable daily sensation. Medications that relieve symptoms may not change long-term prognosis at all.
Why a Blockage Does Not Automatically Require a Procedure: Implementing Optimal Cardiovascular Medical Therapy for Stable Coronary Artery Disease
One of the most consistently surprising findings of modern cardiovascular research is that opening a coronary blockage — with a stent or with bypass surgery — does not always reduce the risk of future heart attack or death in patients with stable coronary disease.
In the COURAGE trial, patients with stable CAD randomised to an initial strategy of percutaneous coronary intervention plus optimal cardiovascular medical therapy for stable coronary artery disease had similar rates of death and myocardial infarction compared with those receiving optimal medical therapy alone.[2] The ISCHEMIA trial extended this finding to patients with stable CAD and moderate-to-severe ischaemia: the invasive strategy did not reduce cardiovascular death, MI, or other hard endpoints compared with a conservative medical strategy over median follow-up of 3.2 years.[3]
The reason is the systemic biology described above. Procedures treat the focal anatomy that imaging reveals. They can restore blood flow, relieve ischaemia-driven symptoms, and in specific high-risk situations — acute coronary syndrome, left main disease, haemodynamic instability, refractory symptoms — they reduce event risk. But they do not modify the biological environment in which every other plaque exists. A stent does not lower ApoB. It does not reduce inflammation. It does not change thrombosis risk in segments it did not touch. Medications do.
This does not mean procedures are unnecessary or that interventional cardiology is wrong. The goal is not to avoid procedures at all costs — it is to understand what each approach actually achieves. Revascularisation is lifesaving or profoundly symptom-improving in the right setting: acute MI, left main disease, multivessel disease with reduced ventricular function, refractory angina despite optimal therapy. The key concept is that procedures and medications address different aspects of coronary disease biology and are genuinely complementary rather than competing strategies.
| Procedures (Stents/Bypass) | Medications | |
|---|---|---|
| What they treat | Focal anatomical obstruction | Systemic disease biology |
| How they work | Restore blood flow mechanically | Modify plaque, thrombosis, haemodynamics, metabolism |
| Best evidence for | ACS, high-risk anatomy, refractory symptoms | All established CAD; primary benefit in stable disease |
| Effect on plaque elsewhere | None | Throughout the coronary tree |
| Time horizon | Immediate-to-medium term | Long-term, cumulative |
Evidence basis: COURAGE[2] and ISCHEMIA[3] for stable CAD; 2023 AHA/ACC guideline for high-risk anatomy and ACS indications.[8] This table is an editorial synthesis of those evidence sources.
The biology does not reset after a procedure. A successful stent does not erase the disease process that created the blockage. Atherosclerosis continues throughout the rest of the coronary tree. This is why medications remain foundational even in patients who have had technically successful interventions.
Why CAD Medications Feel Psychologically Unnatural
Before discussing specific medications, this deserves honest acknowledgement: CAD treatment is psychologically difficult in ways that most medications for other conditions are not.
When someone takes an antibiotic, they feel better within days. An inhaler relieves breathlessness in minutes. A pain medication produces immediate sensation. The feedback is clear and rewarding.
CAD medications often produce none of this. A statin does not create a sensation of plaque shrinking. An antiplatelet does not feel protective. An ACE inhibitor does not announce itself. The patient who takes their medications every day and avoids a heart attack experiences the most successful possible outcome — but success feels exactly like nothing happened. The absence of a catastrophic event is invisible.
This invisibility is one of the primary drivers of non-adherence in cardiovascular medicine. Patients stop medications when they feel fine partly because the medications are working — but the working is imperceptible. The heart attack that the statin prevented does not appear in memory as a benefit. It simply does not occur. And in its absence, the daily inconvenience, the side effects, the cost, and the psychological weight of being “a person who takes heart medications” become increasingly prominent.
CAD treatment is also psychologically difficult because many patients interpret a long medication list as evidence that something is wrong with them, or that previous treatments failed, or that they are deteriorating rather than being protected. The opposite is often true. A carefully constructed multi-agent regimen reflects the multifactorial biology of a systemic disease — not medical uncertainty or failure.
Understanding these psychological dynamics is part of understanding why adherence matters so much and why systems, not willpower, are the solution.
Event Prevention vs Symptom Control
Every cardiovascular medication falls into one of two categories — or both:
Event-preventing therapies reduce the risk of myocardial infarction, stroke, or cardiovascular death. They work through the biology — reducing plaque growth, stabilising plaques, preventing clot formation, or reducing haemodynamic stress. They often produce no daily sensation. Their benefit is long-term and probabilistic: they shift trajectories rather than guarantee outcomes.
Symptom-controlling therapies reduce angina, improve exercise tolerance, and enhance quality of life. They do not change the underlying biology of plaque formation or thrombosis. They do not prevent heart attacks. They make the disease more tolerable day to day.
This distinction is clinically fundamental. Patients are often surprised to learn that some of their most important medications are in the first category — they work silently. Others provide immediate symptom relief but would not appear in any guideline as life-prolonging.
Risk reduction in CAD is probabilistic, not guaranteed. Medications shift the probability of future events. They do not eliminate risk, and an event occurring in a patient on optimal therapy is not evidence that the medications failed — it is evidence that biology involves uncertainty at the individual level. Trials report the benefit of therapy across populations; individual outcomes cannot be predicted with certainty.
Stable CAD vs Acute Coronary Syndrome: Guidelines for Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome
The event-prevention versus symptom-control distinction plays out differently depending on whether the clinical situation is stable or acute. This matters because the medication strategy — particularly antiplatelet intensity — differs substantially between the two.
| Stable Chronic CAD | Acute Coronary Syndrome / Post-Stent | |
|---|---|---|
| Thrombosis risk | Elevated but not acutely heightened | Acutely elevated — healing arterial surface |
| Antiplatelet intensity | Single agent (aspirin) in most | DAPT — two agents for a defined period |
| Initial approach | Medical therapy first in most stable patients | Often invasive evaluation, then medications |
| Event mechanism | Gradual plaque progression; systemic biology | Acute plaque disruption with clot formation |
| Focus of medication strategy | Long-term biology modification | Immediate stabilisation + long-term prevention |
Evidence basis: COURAGE[2] and ISCHEMIA[3] for stable medical-first strategy; 2023 AHA/ACC chronic coronary disease guideline and 2025 ACC/AHA ACS guideline for ACS management.[8,26] This table is an editorial synthesis.
Evaluating the dual antiplatelet therapy duration in acute coronary syndrome highlights this temporary thrombosis window: after ACS or stenting, the biology is temporarily more clot-prone and the arterial surface may be healing — so antiplatelet intensity is higher and more time-sensitive. This window is finite. The long-term systemic biology that drives the disease remains the primary target throughout.
The Logic of Multiple Medications
With the biological framework in place, the logic of combination therapy becomes clear. CAD is a multi-domain disease. No single medication addresses all four biological forces driving it. The combination of medications prescribed after a cardiac event or the discovery of significant coronary disease reflects an attempt to address each domain that meaningfully contributes to recurrent event risk.
The secondary prevention backbone for most patients with established CAD:
| Medication | Biological Target | Prevents Events? | Controls Symptoms? | Usually Temporary or Long-Term? |
|---|---|---|---|---|
| Aspirin | Thrombosis | Yes | No | Long-term in most |
| P2Y12 inhibitor (DAPT) | Thrombosis | Yes | No | Often time-limited |
| High-intensity statin | ApoB burden + plaque stability | Yes | No | Long-term |
| ACE inhibitor/ARB | Haemodynamics + remodelling | Yes (in right phenotype) | No | Phenotype-dependent |
| Beta-blocker | Demand + haemodynamics | Yes (in right phenotype) | Yes | Often reassessed over time |
| Nitrates | Ischaemia symptoms | No | Yes | As needed |
| Colchicine | Inflammation | Yes (selected patients) | No | Long-term (if used) |
| SGLT2 inhibitor | Metabolic/cardiac loading | Yes (with HF/diabetes) | Indirectly | Long-term |
| GLP-1 receptor agonist | Metabolic environment | Yes (with obesity/CVD) | Indirectly | Long-term |
Event-prevention claims reflect key trial evidence: aspirin/DAPT[1,4,18]; statins[14]; ACE inhibitors/ARBs[10]; beta-blockers[8]; colchicine[6,7]; SGLT2 inhibitors[21,22,23]; GLP-1 receptor agonists[12]. Symptom and duration classifications reflect 2023 AHA/ACC guideline.[8] This table is an editorial synthesis.
Understanding what each medication does — and does not do — reframes a complex list into a coherent biological strategy.
What these medications do NOT do:
| Medication | What It Does NOT Do |
|---|---|
| Statins | Do not instantly clear arteries; do not work like “drain cleaner for pipes” |
| Aspirin/antiplatelets | Do not lower cholesterol or reduce plaque burden |
| Nitrates | Do not prevent heart attacks or modify disease progression |
| Beta-blockers | Do not directly reverse plaque or lower LDL |
| GLP-1/SGLT2 agents | Are not substitutes for statin or antiplatelet therapy |
This table is an editorial synthesis to correct common misconceptions; individual claims are supported by the mechanism and trial evidence in each medication section.
How Cardiologists Prioritise Treatment
Treatment intensity and duration are individualised based on ischaemic risk, bleeding risk, symptoms, kidney function, ventricular function, and procedural history. That said, a practical clinical hierarchy guides most decision-making:
Within the first year after ACS or stenting — antiplatelet adherence is the highest-stakes window. The event mechanism during this period is acute thrombosis. Missed doses carry a qualitatively different risk than in most other medication categories. Clinicians treat antiplatelet interruption decisions here with the same seriousness as the procedure itself.
Adhering to high intensity statin therapy guidelines for intensive LDL lowering provides the strongest long-term event reduction signal. The benefit of statins (and add-on agents when needed) is among the most consistently documented in cardiovascular medicine, and the evidence clearly favours intensity. LDL targets kept getting lower as evidence accumulated: each generation of trials demonstrated greater benefit from greater reductions, shifting practice from “treat to 130” to “treat to 70” to “treat to 55” in very high-risk patients.[14,8] This is not medical confusion — it is evidence accumulating in one direction.
Blood pressure control — haemodynamic stress amplifies every other risk factor. Uncontrolled hypertension accelerates endothelial injury, increases myocardial oxygen demand, and promotes adverse ventricular remodelling.[8]
Residual and cardiometabolic therapies — when phenotype indicates. Colchicine, SGLT2 inhibitors, and GLP-1 receptor agonists address specific residual risk domains when the patient’s clinical profile suggests benefit.
Risk stacking matters. CAD risk factors do not simply add — they interact. Modest abnormalities across multiple domains compound over time, and cumulative lifetime exposure to multiple risk factors produces substantially greater atherosclerotic burden than any single factor alone.[8] A patient with mildly elevated LDL, mild hypertension, prediabetes, mild sleep apnoea, and moderate stress is not carrying five separate small risks — they are carrying a cumulative biological load that reflects the interaction of all five. This is why combination therapy addressing multiple domains provides greater benefit than pursuing any single target perfectly while leaving others unaddressed.
Antiplatelet Therapy and Managing Risk Factors for Stent Thrombosis
Biological target: trigger biology — thrombosis prevention. The domain most directly responsible for acute events.
Every antiplatelet decision balances ischaemic protection against bleeding risk. Two patients with identical stents may have different DAPT durations because their bleeding risk differs — not because the evidence is unclear.
Aspirin irreversibly inhibits COX-1 in platelets, blocking thromboxane A2 production and reducing the tendency for platelets to aggregate at sites of disrupted plaque or healing stent surfaces. Low dose (75–100 mg daily) is as effective as higher doses with less gastrointestinal risk.[18] Most patients with established CAD take aspirin long-term.
Dual antiplatelet therapy (DAPT) adds a P2Y12 receptor inhibitor — a second mechanism of platelet inhibition — after ACS or stent placement. Aspirin alone provides insufficient protection against the acute thrombotic risk on a recently disrupted or instrumented coronary surface. The three available P2Y12 agents differ in mechanism, potency, and dosing profile:
| Agent | Key Features |
|---|---|
| Clopidogrel | Requires liver activation; variable response; once daily; widely available generically |
| Ticagrelor | Direct-acting; more consistent inhibition; twice daily; may cause transient dyspnoea |
| Prasugrel | Most potent platelet inhibition; higher bleeding risk in certain populations; once daily |
Agent characteristics per the 2023 AHA/ACC guideline for chronic coronary disease and 2025 ACC/AHA ACS guideline.[8,26]
Duration of DAPT is individualised based on clinical context — ischaemic risk, bleeding risk, stent characteristics, and whether the indication was ACS or elective stenting. Risk-stratification tools can support these decisions.[4] Duration decisions belong to the clinical team, not to patient self-assessment.
Stent thrombosis — clot formation within a stent before the metal surface is covered by healed arterial lining — is uncommon but consequential. When it occurs, it frequently presents as a large myocardial infarction with substantial mortality. Premature discontinuation of antiplatelet therapy is one of the most important modifiable risk factors for stent thrombosis.[8] This is why cardiologists coordinate timing around any planned procedure, dental work, or surgery during the post-stent period. Antiplatelet interruption decisions are not casual — they are risk-stratified, timing-sensitive, and clinician-coordinated.
Domain anchor: antiplatelet therapy addresses trigger biology — the clotting tendency that converts a vulnerable plaque or healing arterial surface into an acute event.
Lipid-Lowering Therapy: Clinical Insights into High Intensity Statin Therapy Guidelines
Biological target: lipoprotein burden (primary) + trigger biology (plaque stabilisation and inflammation reduction).
Lipid-lowering therapy — particularly statins — carries the strongest long-term event reduction signal in cardiovascular medicine. Understanding why requires understanding what these medications actually do biologically.
LDL, ApoB, and cumulative exposure. LDL cholesterol is the standard lab measure, but the underlying causal exposure is ApoB-containing particle burden over time. Every day that atherogenic particles circulate at elevated concentrations, more enter arterial walls, more inflammatory activity is stimulated, and plaque becomes more extensive. The cardiovascular risk associated with elevated LDL is not primarily about today’s number — it is about the total exposure over years and decades.[25] This is why LDL targets kept getting lower as evidence accumulated: each generation of trials demonstrated greater benefit from greater reductions and earlier treatment, shifting practice progressively toward more intensive targets in higher-risk patients.
Statins inhibit HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol synthesis — which upregulates LDL receptors and increases clearance of LDL particles from the circulation. Beyond LDL reduction, statins reduce vascular inflammation and promote plaque stabilisation: the fibrous cap thickens, the lipid core shrinks, and the plaque becomes biologically quieter. This is why statins reduce events even in patients whose LDL appears reasonably controlled — the anti-inflammatory and plaque-stabilising effects are independent of the degree of cholesterol lowering.
Each 1 mmol/L (approximately 39 mg/dL) reduction in LDL produces approximately 22% relative reduction in major vascular events in the CTT meta-analysis of 170,000 participants.[14] Absolute benefit depends on baseline risk and duration of treatment.
Statin intensity describes the expected degree of LDL reduction:
| Intensity | Why It Matters | Expected LDL Reduction |
|---|---|---|
| High | Atorvastatin 40–80 mg; Rosuvastatin 20–40 mg | ≥50% |
| Moderate | Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg | 30–49% |
| Low | Simvastatin 10 mg; Pravastatin 10–20 mg | <30% |
Per the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for Chronic Coronary Disease.[8]
In very high-risk CAD, most frameworks use LDL-C <70 mg/dL (and <55 mg/dL for some very high-risk patients) as thresholds to consider adding non-statin therapy when maximally tolerated statin is insufficient.
Muscle symptoms and the nocebo effect. Muscle symptoms are commonly reported with statin use, but blinded crossover studies — where patients took statin, placebo, and no treatment in randomised sequence without knowing which — found that symptom rates on statin and placebo were nearly identical.[17] This suggests that many perceived statin side effects reflect expectation and social learning, demonstrating the nocebo effect in the context of statin intolerance rather than true pharmacological action. Many patients who report symptoms can tolerate a different statin, a lower dose, or alternate-day dosing. Severe rhabdomyolysis is rare. Clinicians prefer switching rather than stopping whenever possible.
Non-statin agents when statins are insufficient or not tolerated:
Ezetimibe blocks intestinal cholesterol absorption, providing additional LDL reduction when added to statin therapy. IMPROVE-IT demonstrated event reduction when added after ACS.[5]
Clinical trials evaluating pcsk9 inhibitors for secondary prevention in patients with cardiovascular diseases show that these agents (evolocumab, alirocumab) — injectable antibodies that prevent degradation of LDL receptors — substantially lower LDL. Evolocumab reduced cardiovascular events in the FOURIER trial; alirocumab produced similar benefit in the ODYSSEY OUTCOMES trial.[9,27] Reserved for patients not at target despite maximally tolerated statin plus ezetimibe.
Bempedoic acid inhibits an upstream step in cholesterol synthesis and is activated primarily in the liver rather than muscle — making it useful in patients who cannot tolerate statins. CLEAR Outcomes demonstrated event reduction in statin-intolerant patients.[15]
Inclisiran reduces PCSK9 production with twice-yearly dosing, offering an adherence advantage. Cardiovascular outcomes data are less mature than the PCSK9 monoclonal antibody trials.
Domain anchor: lipid-lowering therapy directly addresses lipoprotein burden — the primary substrate of plaque formation — and contributes to plaque stabilisation through anti-inflammatory effects. This is the single domain with the strongest cumulative long-term event reduction signal.
Renin-Angiotensin System Inhibitors: Angiotensin Converting Enzyme (ACE) inhibitors and cardiac remodeling
Biological target: haemodynamic forces + cardiac remodelling protection.
Therapeutic strategies leveraging angiotensin converting enzyme (ace) inhibitors and cardiac remodeling documentation show that these medications block conversion of angiotensin I to angiotensin II, reducing vasoconstriction, fluid retention, and adverse cardiac remodelling. In the HOPE trial, ramipril produced a 22% relative reduction in cardiovascular death, MI, and stroke in high-risk patients.[10] They are particularly important in patients with hypertension, diabetes, chronic kidney disease, or reduced ejection fraction — where both haemodynamic and organ-protective effects are relevant.
Common agents: lisinopril, ramipril, enalapril. Side effects include dry cough (in a minority), hyperkalaemia, and worsening renal function in some patients. Rare but serious: angioedema (swelling of the lips, tongue, or throat) requires immediate emergency evaluation.
ARBs (losartan, valsartan, irbesartan, telmisartan) achieve similar haemodynamic and remodelling effects by blocking the angiotensin II receptor directly, without affecting bradykinin — and therefore without causing cough. Used as the alternative when ACE inhibitor cough is intolerable.
Domain anchor: RAS inhibitors address haemodynamic forces and protect against adverse ventricular remodelling — the structural deterioration that can follow myocardial injury or sustained pressure overload.
Beta-Blockers: Evaluating Beta-Blocker Therapy After Myocardial Infarction
Biological target: haemodynamic forces (heart rate, contractility) + trigger biology (antiarrhythmic protection).
Beta-blockers reduce heart rate, contractility, and blood pressure by blocking the effects of catecholamines. They reduce myocardial oxygen demand, provide antiarrhythmic protection, and — in the post-MI period with reduced ejection fraction — reduce the risk of adverse remodelling and sudden cardiac death.
The survival benefit of beta-blocker therapy after myocardial infarction is clearest when there is an ongoing indication: reduced ejection fraction, early post-MI period, ongoing angina, or significant arrhythmia. The 2023 guideline suggests reassessing the need for continued beta-blocker therapy in patients more than one year post-MI with preserved ejection fraction and no other indication.[8] Much of the original long-term outcome data came from an era of larger infarcts, less reperfusion, and less complete background medical therapy — the benefit in the modern context of preserved EF and optimal medication is genuinely less certain.
Abrupt discontinuation can cause rebound tachycardia and worsening angina. Beta-blockers are typically tapered rather than stopped suddenly.
Common agents: metoprolol succinate, carvedilol, bisoprolol. Side effects include fatigue, cold extremities, bradycardia, and bronchospasm in reactive airway disease.
Domain anchor: beta-blockers address haemodynamic forces — reducing the cardiac work and oxygen demand that determine whether a narrowed artery can maintain adequate supply — and provide antiarrhythmic protection in vulnerable phenotypes.
Symptom-Controlling Therapies
These medications address ischaemia and improve quality of life. They do not prevent cardiovascular events. This distinction matters: a patient whose angina is well-controlled on nitrates is more comfortable, but their underlying disease biology is unchanged.
Nitrates cause vasodilation, reducing cardiac preload and workload. Sublingual nitroglycerin relieves acute episodes within minutes. Long-acting formulations prevent angina with regular use. Critical interaction: combining nitrates with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) can cause profound hypotension and is a major safety contraindication requiring clinician coordination.
Ranolazine reduces ischaemia by affecting late sodium channel activity, lowering myocardial oxygen demand without affecting heart rate or blood pressure. Used when other anti-anginal agents are insufficient.
Calcium channel blockers (amlodipine and others) reduce coronary vasospasm and lower blood pressure. Non-dihydropyridines (diltiazem, verapamil) are generally avoided in combination with beta-blockers because of additive heart rate suppression.
Adjunctive and Cardiometabolic Therapies: Colchicine’s Role in Cardiovascular Disease Management
These therapies address residual risk in patients who remain at elevated event probability despite foundation secondary prevention. Candidates are typically those with prior events, multivessel disease, or persistent risk factors despite standard therapy.
Analyzing colchicine’s role in cardiovascular disease management establishes that it targets trigger biology — specifically inflammation — by inhibiting the NLRP3 inflammasome pathway. COLCOT demonstrated 23% relative event reduction when started within 30 days post-MI.[6] LoDoCo2 showed 31% relative reduction in stable chronic CAD.[7] The 2023 guideline gives colchicine a Class IIb recommendation (“may be considered”) for patients with residual inflammatory risk.[8]
Despite positive trial results, colchicine is not universally adopted. The absolute benefit is modest in lower-risk patients, GI tolerability varies, drug interactions require attention (particularly with macrolide antibiotics and strong CYP3A4/P-gp inhibitors), and the “may be considered” recommendation reflects genuine uncertainty about ideal patient selection. Clinicians vary in how they weigh these factors.
Dual-pathway inhibition: The COMPASS trial demonstrated that adding very low-dose rivaroxaban (2.5 mg twice daily) to aspirin reduced cardiovascular events by 24% in stable atherosclerotic disease, with increased major bleeding but no increase in fatal bleeding.[11] This is distinct from full anticoagulation for atrial fibrillation. Reserved for selected high-risk patients after careful risk-benefit assessment.
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block renal glucose reabsorption, producing favourable effects on cardiac loading, fluid status, and myocardial energetics. Large outcome trials (DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved) demonstrated benefit in heart failure populations independent of diabetes status.[21,22,23] The strongest evidence is for patients with concurrent heart failure or diabetic kidney disease; clinical use of sglt2 inhibitors and coronary artery disease alone without these features is not typically the sole indication.
Current consensus regarding glp-1 receptor agonists and cardiovascular outcomes indicates that these agents (semaglutide, liraglutide, dulaglutide) improve glucose control and reduce weight with cardiovascular benefits that appear partly independent of metabolic effects. The SELECT trial demonstrated 20% relative event reduction with semaglutide in patients with established CVD and obesity without diabetes.[12] The benefit is strongest in the CVD-plus-obesity or CVD-plus-diabetes phenotype.
Domain anchor: these adjunctive therapies address residual trigger biology (colchicine, dual-pathway inhibition) and the metabolic environment (SGLT2, GLP-1) — the domains least fully addressed by the foundation regimen.
Adherence Barriers: Overcoming Challenges to Medication Adherence in Chronic Coronary Syndrome
Every medication described above has one thing in common: it only works when taken. Adherence is addressed here — after the medication-by-medication detail — because understanding what each drug does makes the stakes of consistency concrete. The best regimen in the world provides no protection if it is not consistently taken.
One of the hardest realities in cardiovascular medicine is that many catastrophic events occur in patients who felt reasonably well days earlier. CAD progresses silently. Blood pressure damages arteries without pain. LDL particles accumulate without warning. Feeling fine may mean the medications are working — not that they are no longer needed. Preventive medications often feel unnecessary precisely because they are preventing visible consequences.
A medication only works on the days it reaches the biology.
Suboptimal medication adherence in chronic coronary syndrome is associated with significantly higher rates of recurrent events.[13] Adherence commonly declines over time, often most sharply in the year or two after a cardiac event, when the urgency has faded but the biological need is unchanged.
Why consistency is hard: Motivation depletes. Life becomes busy. Side effects accumulate. The medications feel abstract. And CAD — unlike an infection or an injury — produces no daily symptom that reminds the patient why the medication is there. The solution is not more motivation. It is better systems.
Systems that work:
Friction engineering: medications placed next to a daily habit (coffee, toothbrush) remove the decision from active memory. A weekly pill organiser makes omissions visible at a glance.
Pharmacy systems: automatic refills, medication synchronisation (all refills on the same date), and 90-day supplies prevent the unplanned gaps where risk concentrates. The SECURE trial demonstrated that a polypill strategy — combining multiple secondary-prevention medications into a single tablet — reduced cardiovascular events compared with the same medications given separately, an effect attributed largely to improved adherence.[16]
Objective feedback: knowing that LDL dropped from 130 to 58, or that home blood pressure is consistently controlled, makes the medication feel less abstract and more like a tool that is working. Patients who track one or two metrics tend to sustain adherence better than those who take medications without any visible sign of effect.
Common reasons people stop — and honest responses:
“I feel fine” — the protection is ongoing and invisible. Feeling fine is often evidence the medication is working. Side effects — real, important, and usually addressable with dose adjustment or switching. Clinicians strongly prefer early reporting to silent discontinuation. Cost — generic formulations of the foundation therapies are widely available. Clinicians and pharmacists can identify workable alternatives when cost barriers are raised early. Complexity — solvable with polypills, synchronisation, and habit anchoring. Depression — one of the strongest predictors of non-adherence. If taking medications consistently feels overwhelming, depression may be part of the reason and deserves attention in its own right.
Perfect adherence is not the goal — durable long-term consistency is. Isolated missed doses over years of therapy are not catastrophic in most medication categories. The exception is antiplatelet therapy within the first year after stenting, where the event mechanism is abrupt thrombosis and any planned interruption requires coordination with the cardiology team.
What Medications Cannot Do
Honest framing matters as much as accurate information about what medications achieve.
To establish realistic therapeutic expectations, it is critical to recognize the absolute physiological limits of pharmaceutical interventions:
- Plaque regression limits: Pharmacotherapy cannot eradicate decades of arterial plaque accumulation rapidly; structural regression observed on imaging remains slow and modest.
- Biological versus anatomical outcomes: The definitive value of stabilization therapies lies in rendering plaques biologically quiet and structurally stable, rather than achieving complete anatomical reversal.
- Risk factors persistence: Medications cannot entirely neutralize the vascular damage caused by active smoking, uncontrolled diabetes, or severe obstructive sleep apnea.
- Residual risk trajectory: While baseline risk is lowered substantially during persistent exposures, the absolute probability of an event remains elevated compared to full risk-factor elimination.
Medications reduce risk — they do not create biological invincibility. Patients on optimal medical therapy can still have cardiac events; the evidence demonstrates that the probability of events is meaningfully lower, not zero.
This is not a reason for nihilism — it is a reason for understanding what is being asked of these medications. They are powerful tools that shift long-term trajectories. They are not cures.
Medications Over Time: Temporary vs Long-Term
Understanding which medications are time-limited and which are indefinite prevents misinterpretation when changes occur.
Typically time-limited:
Dual antiplatelet therapy — duration depends on ACS versus elective stenting, bleeding risk, and stent characteristics. Most patients transition from DAPT to single antiplatelet therapy after a defined period.
Beta-blocker — in patients with preserved ejection fraction more than one year post-MI without ongoing angina or arrhythmia, clinicians may reassess the need for continuation.
Typically long-term or indefinite:
Aspirin monotherapy in most patients with established CAD.
Intensive lipid-lowering therapy — the benefit is cumulative and depends on sustained exposure reduction over years.
ACE inhibitor/ARB when indicated by hypertension, diabetes, CKD, or reduced ejection fraction.
The acute vs chronic risk distinction:
| Medication Category | Risk Pattern if Stopped |
|---|---|
| Antiplatelet after stent (early) | Abrupt thrombotic risk — can present as large MI within days to weeks |
| Statin discontinuation | Gradual loss of plaque-stabilising effect; LDL rises over weeks |
| Beta-blocker (abrupt stop) | Vulnerable plaques may cause no sympRebound tachycardia, worsening angina within days |
| ACE inhibitor/ARB discontinuation | Blood pressure rebound; loss of organ protection over weeks |
Risk patterns synthesised from statin discontinuation[14] and 2023 AHA/ACC guideline.[8]
Medical Management at a Glance: Utilizing PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases
The following table consolidates the full medication landscape into a single reference. Each entry links back to the detailed section above; individual clinical decisions are phenotype-dependent and require clinician assessment.
| Medication Class | Biological Domain | Key Evidence | Prevents Events? | Typical Role |
|---|---|---|---|---|
| Aspirin | Thrombosis | Established antiplatelet literature[18] | Yes | Foundation — long-term in most |
| P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) | Thrombosis | DAPT Score[4]; ACS/stent guidelines[8] | Yes | Foundation after ACS/stent — time-limited |
| High-intensity statin | Lipoprotein burden + plaque stability | CTT meta-analysis (170,000 pts)[14] | Yes | Foundation — long-term |
| Ezetimibe | Lipoprotein burden | IMPROVE-IT[5] | Yes (add-on) | Add-on when statin insufficient |
| PCSK9 inhibitor | Lipoprotein burden | FOURIER[9]; ODYSSEY OUTCOMES[27] | Yes | High-risk patients not at LDL target |
| Bempedoic acid | Lipoprotein burden | CLEAR Outcomes[15] | Yes | Statin-intolerant patients |
| ACE inhibitor / ARB | Haemodynamics + remodelling | HOPE[10] | Yes (phenotype-driven) | Hypertension, diabetes, CKD, reduced EF |
| Beta-blocker | Demand + arrhythmia | 2023 guideline[8] | Yes (phenotype-driven) | Post-MI reduced EF; ongoing angina/arrhythmia |
| Nitrates | Ischaemia symptoms | Standard anti-anginal use[8] | No | Symptom control — as needed |
| Ranolazine | Ischaemia symptoms | Standard anti-anginal use[8] | No | Refractory angina add-on |
| Calcium channel blocker | Vasospasm + BP | Standard anti-anginal use[8] | Yes (selected) | Symptom control; BP |
| Colchicine | Inflammation | COLCOT[6]; LoDoCo2[7] | Yes (selected) | Residual inflammatory risk — Class IIb[8] |
| Low-dose rivaroxaban + aspirin | Thrombosis (dual pathway) | COMPASS[11] | Yes (selected) | High-risk stable atherosclerosis |
| SGLT2 inhibitor | Metabolic/cardiac loading | DAPA-HF[21]; EMPEROR[22,23] | Yes (HF/diabetes) | CAD with concurrent HF or diabetes |
| GLP-1 receptor agonist | Metabolic environment | SELECT[12] | Yes (obesity/CVD) | CAD with obesity or diabetes phenotype |
Evidence basis per cited trials and 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for Chronic Coronary Disease.[8] This table is an editorial synthesis — individual clinical decisions are phenotype-dependent and require clinician assessment.
Special Circumstances
Managing coronary artery disease in frail or elderly populations introduces complex clinical variables that demand careful regimen calibration:
- Bleeding complications: Age-related vascular vulnerability increases competing bleeding risks, particularly when deploying intensive antiplatelet regimens.
- Hemodynamic instability: The concurrent use of multiple antihypertensive agents elevates the risk of orthostatic hypotension and subsequent fall hazards.
- Polypharmacy dynamics: Complex drug-to-drug interactions multiply as additional therapies are layered onto preexisting chronic medication profiles.
- Goals-of-care alignment: Therapeutic intensity must be balanced against overall quality of life, patient preferences, and life expectancy.
- Individualized titration: Clinical benefit remains documented in older demographics, but initial dosing and titration speeds frequently require downward modification.
Pregnancy. ACE inhibitors, ARBs, and statins are contraindicated due to fetal harm. Women of childbearing age with CAD require specific counselling and medication planning before pregnancy.
Surgery and procedures. Unplanned antiplatelet interruption — especially within the first year after stenting — carries meaningful thrombotic risk. Timing decisions are clinician-coordinated between cardiology and the procedural team. Many procedures can be performed on aspirin without interruption; P2Y12 inhibitor decisions depend on time since stenting and procedural bleeding risk.
Multiple providers. Patients who carry an updated medication list — including generic names, indication, dose, prescriber, and intended duration — navigate cross-coverage situations (urgent care, emergency visits, travel, hospitalisations) substantially better than those relying on fragmented systems.
Cost barriers. Foundation therapies — aspirin, statins, ACE inhibitors, ARBs, beta-blockers, clopidogrel — are available in generic formulations and are generally low cost. Newer agents (PCSK9 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors) may require prior authorisation or assistance programmes. Early communication with clinicians and pharmacists about cost concerns allows for workable alternatives before gaps occur.
Clinical Monitoring Requirements for SGLT2 Inhibitors and Coronary Artery Disease
Monitoring frequency is individualised based on clinical stability, comorbidities, and dose changes. The following describes common patterns — not a schedule to follow without clinical guidance.
| Medication | What Is Commonly Checked | Typical Approach |
|---|---|---|
| Statins | DiLipid panel; liver enzymes (baseline); CK if symptoms | After dose changes; periodically (every 3–12 months once stable) |
| ACE inhibitors/ARBs | Creatinine, potassium | Shortly after starting or changing; then periodically |
| Beta-blockers | Heart rate, blood pressure | At follow-up visits |
| Antiplatelet agents | VaClinical bleeding assessment | Clinical review at follow-ups |
| Colchicine | Kidney function, haematocrit | Baseline; periodically |
| SGLT2 inhibitors | Kidney function, haematocrit | Baseline; periodically |
Monitoring citations: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for chronic coronary disease.[8]
Common Misconceptions: The nocebo effect in the context of statin intolerance
“Statins are dangerous.” Statins are among the most studied medications in medicine. Serious adverse effects — rhabdomyolysis, significant liver injury — are rare. Blinded crossover studies consistently find that muscle symptom rates on statin and placebo are similar, suggesting many perceived effects involve expectation rather than pharmacology.[17] The cardiovascular benefit in established CAD is substantial and consistently documented across more than 170,000 patients in meta-analysis.[14]
“I’ll take it when my numbers are high and stop when they’re normal.” The statin is not treating a lab value — it is providing ongoing biological protection against plaque progression and instability. Stopping when LDL is “normal” removes the protection that produced the normal number.
“Generics don’t work as well.” Regulatory agencies require generic medications to demonstrate bioequivalence. Systematic reviews of cardiovascular generics confirm no clinically meaningful difference in outcomes.[19]
“Natural supplements are safer alternatives.” Red yeast rice can contain monacolin K — chemically identical to lovastatin — but at variable, unregulated doses. Analyses find substantial variability in active ingredient content between products.[20] For patients needing statin-level LDL reduction, a pharmaceutical statin at a known dose is more reliable than a variable-content supplement.
“If I exercise and eat well, I don’t need these medications.” For primary prevention, lifestyle alone may be sufficient for many people. For established CAD, the evidence is clear that lifestyle plus medications produces superior outcomes to either alone — they address different biological domains of the same disease and their benefits are additive.[2,3,8] See Article 5 for the full discussion of how lifestyle and medications work together.
“Medications failed me because I had another event while taking them.” Risk reduction is probabilistic. Medications lower the probability of events; they do not eliminate it. An event occurring in a patient on optimal therapy is not evidence of failure — it reflects the underlying biology of a disease that reduces but does not abolish risk. Clinicians respond to such events by reassessing and often intensifying therapy, not by concluding that treatment is futile.
How Pharmacists Support CAD Patients
Pharmacists are an underutilised resource. They review drug interactions before new medications or supplements are started, assist with adherence packaging (blister packs, synchronised refill dates), advise on OTC products compatible with cardiac regimens, identify lower-cost alternatives and patient assistance programmes, and provide 90-day supplies that reduce gaps. Patients often find pharmacists accessible for quick questions without an appointment.
Questions to Bring to Visits
Understanding your regimen enables more productive clinical conversations:
About your regimen: What is my LDL, and what threshold are we using for escalation? Am I on high-intensity statin therapy? How long do I need dual antiplatelet therapy? Which medications are lifelong?
About optimisation: Are there newer therapies — colchicine, PCSK9 inhibitors, SGLT2 inhibitors — I should consider? My LDL is still above target — what are my options?
About side effects: Could this symptom be from one of my medications? If I cannot tolerate this agent, what are the alternatives?
About coordination: I am scheduled for a procedure — what do I need to do about my antiplatelets? Can I have an updated medication list with generic names to carry with me?
What Success Looks Like: Maximizing GLP-1 Receptor Agonists and Cardiovascular Outcomes
A regimen that is evidence-based, tolerable, affordable, and simple enough to sustain for years — paired with monitoring that confirms it is working. In CAD, the best regimen is not the most aggressive on paper. It is the one that addresses the key biological domains, produces acceptable tolerability, and can realistically be maintained over a long time horizon.
Success in CAD is often invisible. It is the absence of the event that the statin prevented, the clot that the antiplatelet interrupted, the remodelling that the ACE inhibitor slowed. The patient who takes their medications every day, adjusts their lifestyle, and lives for another decade without a second heart attack has often gained something more than statistics: better functional capacity, more stable symptoms, and the confidence that comes from understanding their own biology and acting on it. The magnitude of that benefit only becomes fully visible when you run the numbers — but it is being earned every day.
Modern cardiovascular medicine does not aim to fix one blockage and restore the patient to baseline. It aims to modify the systemic biological environment in which every plaque exists — reducing the forces driving progression, stabilising the biology that determines whether plaques rupture, and managing the domains that convert chronic disease into acute events. Medications are the tools for that biology. They work best when they reach it consistently, over time.
Key Terms
ACS (Acute coronary syndrome): Unstable angina or myocardial infarction — caused by acute plaque disruption and clot formation.
ApoB: Apolipoprotein B — a protein carried by every atherogenic lipoprotein particle; measuring ApoB estimates total particle burden, which may better predict cardiovascular risk than LDL-C alone in some patients.
DAPT (Dual antiplatelet therapy): Aspirin plus a P2Y12 inhibitor — used after ACS or coronary stenting to reduce the risk of acute thrombosis on the healing arterial surface.
Ejection fraction (EF): The percentage of blood pumped out of the left ventricle with each heartbeat; a measure of cardiac pump function.
Guideline recommendation class: See Article 4 Key Terms for a complete definition. Class I = recommended; Class IIa = reasonable; Class IIb = may be considered; Class III = not recommended.
Nocebo effect: The phenomenon by which negative expectations produce real symptoms — the physiological mirror of the placebo effect. Relevant to statin side effect reporting.
Phenotype: A patient’s observable clinical characteristics — presence of heart failure, diabetes, kidney disease, inflammatory risk — that determine which therapies are most appropriate beyond the foundation regimen.
PCSK9 inhibitor: A class of injectable antibody medications that prevent the degradation of LDL receptors, substantially lowering circulating LDL. Used in patients not at LDL target despite maximally tolerated statin and ezetimibe.
Remodelling: Structural changes in the heart muscle — often adverse, involving wall thinning and chamber dilation — that can follow myocardial injury or sustained haemodynamic stress. Prevented or attenuated by ACE inhibitors and beta-blockers.
Secondary prevention: Treatment to prevent recurrent events in patients with established cardiovascular disease.
Stent thrombosis: Clot formation within a coronary stent before the metal surface is fully covered by healed arterial tissue. Uncommon but frequently presenting as large MI. Premature antiplatelet discontinuation is a primary modifiable risk factor.
References
- Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907. https://doi.org/10.1016/j.jacc.2010.07.028
- Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease (COURAGE). N Engl J Med. 2007;356(15):1503–1516. https://doi.org/10.1056/NEJMoa070829
- Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med. 2020;382(15):1395–1407. https://doi.org/10.1056/NEJMoa1915922
- Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy (DAPT Score). JAMA. 2016;315(16):1735–1749. https://doi.org/10.1001/jama.2016.4679
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489
- Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT). N Engl J Med. 2019;381(26):2497–2505. https://doi.org/10.1056/NEJMoa1912388
- Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease (LoDoCo2). N Engl J Med. 2020;383(19):1838–1847. https://doi.org/10.1056/NEJMoa2021372
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148(9):e9–e119. https://doi.org/10.1161/CIR.0000000000001168
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713–1722. https://doi.org/10.1056/NEJMoa1615664
- Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE). N Engl J Med. 2000;342(3):145–153. https://doi.org/10.1056/NEJM200001203420301
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS). N Engl J Med. 2017;377(14):1319–1330. https://doi.org/10.1056/NEJMoa1709118
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563
- Kolandaivelu K, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35(46):3267–3276. https://doi.org/10.1093/eurheartj/ehu364
- Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353–1364. https://doi.org/10.1056/NEJMoa2215024
- Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention (SECURE). N Engl J Med. 2022;387(11):967–977. https://doi.org/10.1056/NEJMoa2207353
- Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210–1222. https://doi.org/10.1016/j.jacc.2021.07.022
- Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–2383. https://doi.org/10.1056/NEJMra052717
- Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514–2526. https://doi.org/10.1001/jama.2008.758
- Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware. Arch Intern Med. 2010;170(19):1722–1727. https://doi.org/10.1001/archinternmed.2010.382
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107938
- Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis (PROSPECT). N Engl J Med. 2011;364(3):226–235. https://doi.org/10.1056/NEJMoa1002358
- Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease. J Am Coll Cardiol. 2012;60(25):2631–2639. https://doi.org/10.1016/j.jacc.2012.09.017
- Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862. https://doi.org/10.1161/CIR.0000000000001309
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097–2107. https://doi.org/10.1056/NEJMoa1801174
HeartBuddi • Your heart. Own it.